Some thoughts before the July 31st.  * Is the #C4CT

New Post Public Reply Private Reply Replies (2) Message Board
Mauibound

Some thoughts before the July 31st. 

* Is the #C4CT website up to date?
* Is Dr. Kirby presenting on behalf of the company, per GC
* if he is, is Dr. Kirby being introduced as a BOA or CMO
I have emailed Aimee with the above questions and will post any updates or responses.

Questions I don't have an answers to:

Can the Gov't give Grants or Contracts to not yet Approved FDA diagnostic tests?

IE - Fed grants or contracts for testing soldiers 

"As we prepare to launch our blood diagnostic LymPro Test ® for Alzheimer's disease in the second half of 2014, we believe it is critical to identify populations who are at the highest risk of developing Alzheimer's disease so that we may conduct clinical research to identify common pathways among those who progress to Alzheimer's disease," said Gerald E. Commissiong, President & CEO of Amarantus. "Traumatic Brain Injury is a clear risk factor that we believe accelerates an already-present predisposition for Alzheimer's disease. Current and former athletes and soldiers who have been exposed to multiple concussions and sub-concussive events should be on high alert for symptomatology of early Alzheimer's disease."

As mentioned in the PR specifically attached w/the #C4CT Summit.
http://www.marketwatch.com/story/amarantus-an..._news_stmp

Without getting into ANY political debates, with having The Honorable Chaka Fattah Member of Congress giving the Opening Keynote Address and his personal mission in wanting to address Alzheimer's, TBI and the correlation to the two, I wonder is there is a connection that we do not know about.

GC has said many times over in essence  -
I don't worry about share price. Let the science speak for itself.

And yet, he is the one when asked 
"@G_Commish Estimate of range of where you'd like see share price before reverse split/up-list? Glad it's in 2015."
GC voluntarily offers up ".@eyedo_2015 We do not know a reverse is needed. #AskAMBS"

https://mobile.twitter.com/G_Commish/status/4...8794665984

The worst thing a small co. can do is call attention to itself on a global scale and produce failing numbers. GC has intimated this, so why on Earth would he 
A) Intro $AMBS at AAIC 
B) let it be known he will be delivering new updated #'s at the #C4CT
C) bring up the idea of possibly NOT needing an R/S
D) bring up the terms like  Financial Engineering 
E) continually speak of taking care of long term investors
F) have an unwavering stance that LymPro Test(R) to market & up listing will both happen 2H14

He would have to be an absolute CLOWN to continually make remarks and statements that are so entirely outlandish and FALSE,  no?

That's crazy talk, though, none are promises, but legitimate goals set forth by him. For whatever reasoning, he sees it as financially plausible.

What news will be coming out soon regarding MANF. Not JV or partnering or even grants, all possible too, but as in research in regards to:

Wolfram's Syndrome and MANF as Dr. Urano aims to cure! As in eradicate a disease. 

Scientists rarely take time to celebrate, Japanese scientists celebrate even less, because the science is not about them, it's about their team, the disease and the common goal to eradicate that disease. 

So, for Dr. Urano to publicly announce he has just submitted a paper and show himself "celebrating", that speaks volumes.

"Just sent out an research article on Wolfram syndrome. Cheers!"  Fumi instagram.com/p/qSvNTztW1N/
6:44pm - 10 Jul 14

And then to follow it up by Stating his intentions of coming up with a cure and the process will be TROUGH MANF, well I don't have a clue what else anyone needs to be reassured in this company, the people who are running it, associated with it  and everyone on the forefront of finding cures...

Oh and last before I get off my soapbox for the day, Any CLOWN who refers to that other test AMYVID other than AMYVID is dismissing and degrading every single person who has worked on it  and every single patient and family member that is dealing or has dealt with that disease.
Refer to it by its proper name you Arrogant CLOWN and pay respects to the community who is working on helping those who are suffering!

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Updated Category News Views 7

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

Continue Reading
Atli Launches: AI-Powered eSIM Revolutionizes Travel

Updated Category News Views 5

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Continue Reading
Red-Eye Flights Surge, Driven By Western U.S. Routes

Updated Category News Views 5

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Continue Reading
Merit Advisors Shines as Top Energy Workplace

Updated Category News Views 1

Well, here's something to chew on—Merit Advisors just grabbed the top spot on Hart Energy's first-ever Best Places to Work in Energy list. If you haven't heard of them, Merit's the heavyweight champ in specialty tax for the energy sector. This isn't just a shiny trophy on the shelf; it's a nod to the kind of culture that's making waves in an industry that's no stranger...

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 3

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading
CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Updated Category News Views 12

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Continue Reading
GBI Bio's New CEO Jesse McCool to Propel Growth

Updated Category News Views 4

Jesse McCool stepping into GBI's CEO shoes is the kind of move that makes you sit up straight and take notice. Let me tell you, the biomanufacturing scene is buzzing with this appointment, and McCool's got his work cut out for him in leading GBI Biomanufacturing's shift towards commercial-scale operations while expanding their early-stage biotech portfolio. A Veteran in...

Continue Reading
Moore Law Investigates Aardvark Therapeutics' Risks

Updated Category News Views 2

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Continue Reading
World Fire Congress 2026 Champions Global Fire Safety

Updated Category News Views 1

Rethinking Fire Safety with a Global Mindset The 2026 World Fire Congress wrapped up in London, signaling a big shift in how we tackle fire safety. Over 60 nations were represented, and they all walked away singing the same tune: if we’re going to handle these ever-mounting fire risks, we have to lean on each other a lot more. Next stop on this crusade? The flashy city...

Continue Reading
Havoc, CSBC Partner for Autonomous Maritime Future

Updated Category News Views 5

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Continue Reading

Top 5 Most Recently Viewed Articles

Cheers Act: Revamping America's Bars and Restaurants

Updated Category News Views 598

Understanding the CHEERS Act and Its Impact The CHEERS Act, or the Creating Hospitality Economic Enhancement for Restaurants and Servers Act, has gained traction in Washington, D.C., thanks to bipartisan support from key legislators. The initiative aims to provide essential tax relief to bars, restaurants, taprooms, and entertainment venues that incorporate draft beer...

Continue Reading
Harnessing AI for Enhanced Content Automation Solutions

Updated Category News Views 151

The Transformative Role of AI in Content Automation As we step into a new era characterized by rapid technological advancement, artificial intelligence (AI) is revolutionizing the realm of content automation. Businesses across various sectors are increasingly leveraging AI to streamline their content creation processes, resulting in a more efficient workflow and...

Continue Reading
Urgently Inc. Announces Impressive Q1 2025 Financial Overview

Updated Category News Views 235

Urgently Inc. Reports Financial Highlights for First Quarter 2025 Urgently Inc. (NASDAQ: ULY), a notable provider of digital roadside assistance technologies, has officially released its financial results for the first quarter. The results indicate a strong start to the fiscal year, highlighted by significant improvements across various financial metrics. Key Financial...

Continue Reading
Implantica's Breakthrough Study Results Propel RefluxStop™ Forward

Updated Category News Views 62

Results of Implantica's Innovative CE Mark Study Implantica AG (publ.) is a leading medtech company known for its innovative healthcare solutions. Their focus centers on the RefluxStop™ device, designed specifically to treat acid reflux, a condition that affects over one billion people worldwide. Recently, Implantica completed a comprehensive five-year CE mark study,...

Continue Reading
Pye-Barker Expands with the Acquisition of Systems Design Group

Updated Category News Views 116

Pye-Barker Fire & Safety Expands Its Reach Pye-Barker Fire & Safety has made a significant move to enhance its service capabilities by acquiring Systems Design Group (SDG). This acquisition marks an important milestone for Pye-Barker as they continue to grow as the premier provider of fire protection and life safety services across the nation. Enhancing Customer Service...

Continue Reading